AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Sellas Life Sciences Group Inc (NASDAQ:SLS)
1.13 USD
-0.040 3.419%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.17 |
|---|---|
| Change | -0.040 3.419% |
| 52 W H/L (in USD) | 1.914/0.499 |
| EBITDA (in USD) | -- |
| PE Ratio | -- |
| Volume | 917893 |
| Diluted Eps TTM | -1.08 |
| Total Assets (in USD) | 6.403M |
|---|---|
| Total Liabilities (in USD) | 14.379M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 2.63M |
| Market Cap (in USD) | 79.702 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | 0.9M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Times Square Tower, New York, NY, United States, 10036
646 200 5278
Employees: 16
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, Pres, CEO & Director | 1976 |
| 2. | Ms. Barbara A. Wood | Exec. VP, Gen. Counsel & Sec. | 1963 |
| 3. | Dr. Dragan Cicic M.D., MBA | Sr. VP of Clinical Devel. | 1963 |
| 4. | Mr. John Thomas Burns CPA | Sr. VP of Fin. & Chief Accounting Officer | 1985 |
| 5. | Mr. Robert M. Francomano | Sr. VP & Chief Commercial Officer | 1967 |
| 6. | Mr. Jörg W. Breitkopf | Head of Clinical Operations | NA |
| 7. | Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, CEO & Director | 1976 |
| 8. | Mr. John Thomas Burns CPA | Senior VP & CFO | 1985 |
| 9. | Ms. Stacy E. Yeung | VP, Associate General Counsel & Head of Compliance | NA |
| 10. | Dr. Dragan Cicic M.D., MBA | Senior Vice President of Clinical Development | 1963 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.670 0.631% | 105.43 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.005 0.005% | 105.38 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.570 0.769% | 463.6 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-4.650 0.616% | 746.62 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -41.301M | -20.936M | -16.774M | -19.373M | -29.048M |
| Minority Interest | - | - | - | - | - |
| Net Income | -40.652M | -20.699M | -16.757M | -19.292M | -27.67M |
| Selling General Administrative | 12.582M | 11.32M | 9.6M | 9.923M | 12.772M |
| Gross Profit | 0.9M | 7.4M | 0.002M | - | 0M |
| Reconciled Depreciation | - | - | 0.282M | - | 0M |
| Ebit | -41.95M | -25.294M | -16.757M | -20.041M | -35.703M |
| Ebitda | -42.282M | -29.646M | 26.524M | -14.925M | -33.396M |
| Depreciation And Amortization | -0.332M | -4.352M | 0.282M | 5.116M | 2.307M |
| Operating Income | -41.95M | -25.294M | -16.982M | -20.041M | -31.089M |
| Other Operating Expenses | 42.95M | 32.894M | 18.882M | 17.208M | 31.089M |
| Interest Expense | -0.649M | 4.358M | 0.39M | 0.118M | 0.266M |
| Tax Provision | 0M | -0.237M | -0.017M | -0.081M | -1.378M |
| Interest Income | 0.317M | 0.006M | 0.026M | 0.118M | 0.266M |
| Net Interest Income | 0.317M | 0.006M | 0.026M | 0.118M | -0.266M |
| Income Tax Expense | -0.649M | -0.237M | -0.017M | -0.081M | -1.378M |
| Total Revenue | 1M | 7.6M | 0.002M | 0M | 0M |
| Total Operating Expenses | 42.85M | 32.694M | -18.882M | 17.208M | 31.089M |
| Cost Of Revenue | 0.1M | 0.2M | - | - | 0M |
| Total Other Income Expense Net | 0.649M | 4.358M | 16.965M | 0.668M | 2.307M |
| Net Income From Continuing Ops | -41.301M | -20.699M | -16.757M | -19.292M | -27.648M |
| Net Income Applicable To Common Shares | -41.301M | -20.699M | -16.835M | -27.951M | -41.251M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 6.403M | 20.943M | 26.275M | 46.049M | 16.609M |
| Intangible Assets | - | - | - | 5.7M | 5.7M |
| Other Current Assets | 0.542M | 0.046M | 0.027M | 0.03M | 0.084M |
| Total Liab | 14.379M | 16.092M | 5.928M | 18.088M | 10.516M |
| Total Stockholder Equity | -7.976M | 4.851M | 20.347M | 27.961M | 6.093M |
| Other Current Liab | 7.65M | 11.786M | 0.161M | 1.913M | 1.171M |
| Common Stock | 0.003M | 0.002M | 0.002M | 0.001M | 0.005M |
| Capital Stock | 0.003M | 0.002M | 0.002M | 0.001M | 0.005M |
| Retained Earnings | -217.244M | -179.904M | -138.603M | -117.904M | -101.147M |
| Good Will | 1.914M | 1.914M | 1.914M | 1.914M | 1.914M |
| Other Assets | 0M | 0.399M | 0.594M | 7.21M | 0.536M |
| Cash | 2.63M | 17.125M | 21.355M | 35.302M | 7.277M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 13.735M | 15.515M | 4.982M | 12.336M | 5.29M |
| Current Deferred Revenue | - | - | 2.479M | 5.6M | - |
| Net Debt | -1.724M | -16.18M | -20.547M | -34.311M | -7.06M |
| Short Term Debt | 0.446M | 0.372M | 0.198M | 0.166M | 0.217M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 0.906M | 0.945M | 0.808M | 0.991M | 0.217M |
| Other Stockholder Equity | 209.265M | 184.753M | 158.948M | 145.864M | 107.235M |
| Property Plant Equipment | - | 0.874M | 0.723M | 0.896M | 0.217M |
| Total Current Assets | 3.172M | 17.756M | 23.044M | 36.925M | 8.242M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | - | - | - | 1.128M | 0.308M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | 0.465M | 0.573M |
| Accounts Payable | 5.639M | 3.357M | 2.144M | 4.657M | 3.902M |
| Accumulated Other Comprehensive Income | - | - | - | - | - |
| Non Currrent Assets Other | 0.275M | 0.399M | 0.594M | 0.614M | 0.536M |
| Non Current Assets Total | 3.231M | 3.187M | 3.231M | 9.124M | 8.367M |
| Capital Lease Obligations | 0.906M | 0.945M | 0.808M | 0.991M | 0.217M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -4.5M | - | - | - | 0M |
| Total Cashflows From Investing Activities | -4.5M | -4.5M | -4.5M | -4.5M | - |
| Total Cash From Financing Activities | 24.079M | 12.074M | 38.442M | 19.569M | 23.123M |
| Net Income | -41.301M | -20.699M | -16.757M | -19.292M | -27.67M |
| Change In Cash | -4.23M | -13.947M | 28.025M | 1.926M | -7.299M |
| Begin Period Cash Flow | 21.455M | 35.402M | 7.377M | 5.451M | 12.75M |
| End Period Cash Flow | 17.225M | 21.455M | 35.402M | 7.377M | 5.451M |
| Total Cash From Operating Activities | -23.809M | -26.021M | -10.417M | -17.643M | -30.422M |
| Depreciation | - | 5.685M | 0.282M | 1.697M | 3.759M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | 0M | 0.487M |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | 38.134M | 19.569M | 31.211M |
| Other Cashflows From Financing Activities | 0.085M | 3.069M | 8.843M | 3.598M | 9.647M |
| Capital Expenditures | 4.5M | 0M | 0M | 0M | 0M |
| Change In Working Capital | 5.641M | -7.615M | 5.59M | -1.112M | -10.006M |
| Other Non Cash Items | 10.125M | -4.164M | -0.087M | 0.586M | 4.416M |
| Free Cash Flow | -28.309M | -26.021M | -10.417M | -17.643M | -30.422M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 1211353 |
| 2. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 412707 |
| 3. | Fidelity Extended Market Index | 8 months ago | 147940 |
| 4. | iShares Micro-Cap ETF | 7 months ago | 58248 |
| 5. | NT Ext Equity Mkt Idx Fd - L | 8 months ago | 49801 |
| 6. | Northern Trust Extended Eq Market Idx | 8 months ago | 49801 |
| 7. | BlackRock Extended Mkt Composite | 1 year ago | 41609 |
| 8. | Fidelity Series Total Market Index | 8 months ago | 39111 |
| 9. | Fidelity Total Market Index | 8 months ago | 36800 |
| 10. | NT Ext Equity Mkt Idx Fd - NL | 8 months ago | 36517 |
| 11. | BlackRock Extended Equity Market K | 8 months ago | 36313 |
| 12. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 11 months ago | 29328 |
| 13. | Fidelity Nasdaq Composite Index | 8 months ago | 22014 |
| 14. | Spartan Extended Market Index Pool E | 8 months ago | 19334 |
| 15. | Schwab Total Stock Market Index | 7 months ago | 16238 |
| 16. | Vanguard Instl Ttl Stck Mkt Idx Tr | 8 months ago | 14948 |
| 17. | State St US Extended Mkt Indx NL Cl C | 7 months ago | 9475 |
| 18. | SSgA U.S. Extended Market Index Class I | 11 months ago | 9475 |
| 19. | Spartan Total Market Index Pool E | 8 months ago | 7657 |
| 20. | Vanguard U.S. Eq Idx £ Acc | 7 months ago | 6343 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Group Inc | 8 months ago | 1513235 |
| 2. | Armistice Capital, LLC | 11 months ago | 820000 |
| 3. | BlackRock Inc | 11 months ago | 279804 |
| 4. | Geode Capital Management, LLC | 11 months ago | 245603 |
| 5. | Opus Capital Group LLC | 8 months ago | 200600 |
| 6. | Group One Trading, LP | 11 months ago | 186355 |
| 7. | Equitable Holdings Inc | 11 months ago | 165000 |
| 8. | State Street Corporation | 11 months ago | 97129 |
| 9. | Bank of New York Mellon Corp | 11 months ago | 84665 |
| 10. | Northern Trust Corp | 11 months ago | 62437 |
| 11. | Virtu Financial LLC | 11 months ago | 59914 |
| 12. | Renaissance Technologies Corp | 11 months ago | 50400 |
| 13. | XTX Topco Ltd | 11 months ago | 42570 |
| 14. | Prosperity Financial Group, INC. | 8 months ago | 25385 |
| 15. | Engineers Gate Manager LP | 11 months ago | 16857 |
| 16. | Wells Fargo & Co | 11 months ago | 16357 |
| 17. | Charles Schwab Investment Management Inc | 8 months ago | 16238 |
| 18. | TWO SIGMA SECURITIES, LLC | 11 months ago | 15304 |
| 19. | Commonwealth Equity Services Inc | 11 months ago | 12414 |
| 20. | JPMorgan Chase & Co | 11 months ago | 9793 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
